IN2014DN02346A - - Google Patents

Info

Publication number
IN2014DN02346A
IN2014DN02346A IN2346DEN2014A IN2014DN02346A IN 2014DN02346 A IN2014DN02346 A IN 2014DN02346A IN 2346DEN2014 A IN2346DEN2014 A IN 2346DEN2014A IN 2014DN02346 A IN2014DN02346 A IN 2014DN02346A
Authority
IN
India
Prior art keywords
dosage forms
oral dosage
compositions
enylamino
chloro
Prior art date
Application number
Other languages
English (en)
Inventor
Ameet Vijay Ambarkhane
Arnaud Mauler
Carsten Timpe
Urs Baettig
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN02346A publication Critical patent/IN2014DN02346A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN2346DEN2014 2011-09-02 2012-08-31 IN2014DN02346A (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530516P 2011-09-02 2011-09-02
PCT/IB2012/054502 WO2013030803A1 (en) 2011-09-02 2012-08-31 Choline salt of an anti - inflammatory substituted cyclobutenedione compound

Publications (1)

Publication Number Publication Date
IN2014DN02346A true IN2014DN02346A (pl) 2015-05-15

Family

ID=47116123

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2346DEN2014 IN2014DN02346A (pl) 2011-09-02 2012-08-31

Country Status (17)

Country Link
US (1) US9018261B2 (pl)
EP (2) EP2760821B1 (pl)
JP (3) JP2014529621A (pl)
KR (1) KR102024955B1 (pl)
CN (1) CN103842330B (pl)
BR (1) BR112014004963A2 (pl)
CA (1) CA2846510C (pl)
EA (1) EA201490552A1 (pl)
ES (1) ES2655942T3 (pl)
HU (1) HUE035751T2 (pl)
IN (1) IN2014DN02346A (pl)
MX (1) MX359259B (pl)
NO (1) NO2679622T3 (pl)
PL (1) PL2760821T3 (pl)
PT (1) PT2760821T (pl)
SI (1) SI2760821T1 (pl)
WO (1) WO2013030803A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Cxcr2抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
US11207294B2 (en) 2018-01-08 2021-12-28 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
BR112022021269A2 (pt) * 2020-04-24 2022-12-06 Dr Falk Pharma Gmbh Formulação sistêmica, composto e composição farmacêutica para uso
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506252A (en) 1993-11-17 1996-04-09 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
AU686896B2 (en) 1994-11-16 1998-02-12 American Home Products Corporation Diaminocyclobutene-3,4-diones
WO1998033763A1 (en) 1997-01-30 1998-08-06 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US5840764A (en) 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
FR2815345B1 (fr) 2000-10-12 2002-12-13 Servier Lab Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0028844D0 (en) 2000-11-27 2001-01-10 Celltech Chiroscience Ltd Chemical compounds
WO2002067919A1 (en) 2001-01-16 2002-09-06 Smithkline Beecham Corporation Il-8 receptor antagonists
AR032398A1 (es) 2001-01-16 2003-11-05 Smithkline Beecham Corp Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
WO2002062761A1 (en) 2001-02-07 2002-08-15 Abbott Laboratories Aminal diones as potassium channel openers
US20040110954A1 (en) 2001-03-30 2004-06-10 Palovich Michael R. Methods of synthesizing phenol-contining compounds
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
RU2344123C9 (ru) 2001-04-16 2009-05-20 Шеринг Корпорейшн 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора
WO2003000245A1 (en) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
EP1485089B1 (en) 2002-03-18 2013-04-17 Merck Sharp & Dohme Corp. Combination treatments for chemokine-mediated diseases
WO2005004915A2 (en) * 2003-07-09 2005-01-20 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam
CA2554709C (en) 2004-01-30 2011-11-15 Schering Corporation Crystalline polymorphs of a cxc-chemokine receptor ligand
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
GB0407908D0 (en) * 2004-04-07 2004-05-12 Univ York Ionic liquids
DE102004046492A1 (de) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
ES2327840T3 (es) 2004-12-23 2009-11-04 Gpc Biotech Ag Derivados de acido escuarico con actividad antiproliferativa.
DE102005001053A1 (de) 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
JP2008530284A (ja) 2005-02-10 2008-08-07 ワッカー ケミー アクチエンゲゼルシャフト 保護されたイソシアネート基を有する粒子を含有する塗料
CA2598460C (en) 2005-02-16 2013-05-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
DE102005035741A1 (de) 2005-07-29 2007-02-08 Merck Patent Gmbh Quadratsäurederivate
CN101511809A (zh) 2006-07-07 2009-08-19 先灵公司 作为cxc-趋化因子受体配体的3,4-二取代的环丁烯-1,2-二酮
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
AU2008223348A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
US8183281B2 (en) 2007-06-06 2012-05-22 Novartis Ag CXC-chemokine receptor ligands
CA2692269A1 (en) 2007-07-03 2009-01-08 Schering Corporation Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
CA2694268A1 (en) 2007-07-05 2009-01-08 Schering Corporation Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
EP2252327A2 (en) 2007-12-04 2010-11-24 Schering Corporation Methods of treating copd
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
WO2010002418A2 (en) * 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作c型肝炎病毒抑制劑之巨環吲哚衍生物
SI2307376T1 (sl) 2008-08-04 2016-02-29 Merck Patent Gmbh Nove spojine fenilamino izonikotinamida
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
RU2011123377A (ru) * 2008-11-14 2012-12-20 Портола Фармасьютиклз, Инк. ТВЕРДАЯ КОМПОЗИЦИЯ ДЛЯ КОНТРОЛИРУЕМОГО ВЫСВОБОЖДЕНИЯ АКТИВНЫХ ИОНИЗИРУЕМЫХ АГЕНТОВ, ХАРАКТЕРИЗУЮЩИХСЯ НИЗКОЙ РАСТВОРИМОСТЬЮ В ВОДЕ ПРИ НИЗКИХ ЗНАЧЕНИЯХ pН, И СПОСОБЫ ЕЕ ПРИМЕНЕНИЯ
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists

Also Published As

Publication number Publication date
PL2760821T3 (pl) 2018-04-30
MX2014002492A (es) 2014-05-28
JP6612200B2 (ja) 2019-11-27
US9018261B2 (en) 2015-04-28
JP2019001787A (ja) 2019-01-10
WO2013030803A1 (en) 2013-03-07
US20140206768A1 (en) 2014-07-24
CA2846510A1 (en) 2013-03-07
HUE035751T2 (hu) 2018-08-28
KR102024955B1 (ko) 2019-09-24
KR20140059264A (ko) 2014-05-15
PT2760821T (pt) 2018-01-11
CN103842330B (zh) 2016-10-19
JP2014529621A (ja) 2014-11-13
CN103842330A (zh) 2014-06-04
EA201490552A1 (ru) 2014-11-28
BR112014004963A2 (pt) 2017-03-21
EP3287438A1 (en) 2018-02-28
EP2760821B1 (en) 2017-10-11
CA2846510C (en) 2019-10-22
ES2655942T3 (es) 2018-02-22
NO2679622T3 (pl) 2018-01-20
JP2017025081A (ja) 2017-02-02
EP2760821A1 (en) 2014-08-06
SI2760821T1 (en) 2018-02-28
MX359259B (es) 2018-09-20

Similar Documents

Publication Publication Date Title
MX2014002492A (es) Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida.
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MX349159B (es) Derivados deuterados de ivacaftor.
IN2014MN00988A (pl)
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
GT201400016A (es) Indazoles
IN2014MN00948A (pl)
EP2552203A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
CR20140134A (es) Composiciones farmacéuticas
UA109667C2 (xx) Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
BR112013019256A2 (pt) inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune
EP2696874A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NOSES
BR112013029730A2 (pt) composição farmacêutica de rosuvastatina cálcica
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
EP3060220A4 (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
FR2981572B1 (fr) Compositions pharmaceutiques d'acide ursodesoxycholique